Publications by authors named "Gemma Jones"

Claim this Profile
N
No evidence of MMR induced trained immunity to prevent SARS COV2: results from a multi-centre RCT.
Sinead Delany-Moretlwe, Hakim-Moulay Dehbi, Izukanji Sikazwe, George Kyei, Kwadwo Koram, Gemma Jones

Front Immunol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic Evaluations of Speech and Language Therapy Interventions: A Scoping Review.
James Hill, Amit Kulkarni, Deborah Moll, Lotte Meteyard, Louise Shelley, Gemma Jones

Int J Lang Commun Disord· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 5-Year Review of a Tracheostomy Quality Improvement Initiative: Reducing Adverse Event Frequency and Severity.
Paul Twose, Julia Cottam, Gemma Jones, Jennifer Lowes, Jason Nunn

Otolaryngol Head Neck Surg· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Valproic Acid Confers Functional Pluripotency to Human Amniotic Fluid Stem Cells in a Transgene-free Approach.
Dafni Moschidou, Sayandip Mukherjee, Michael P Blundell, Katharina Drews, Gemma N Jones

Mol Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.
Elizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar, Devon Taylor, Marta Milo, Gemma N Jones

Nat Commun· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation.
Magnus T Dillon, Jeane Guevara, Kabir Mohammed, Emmanuel C Patin, Simon A Smith, Gemma N Jones

J Clin Invest· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models.
Ankur Karmokar, Rebecca Sargeant, Adina M Hughes, Hana Baakza, Zena Wilson, Gemma N Jones

Cancers (Basel)· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epitope Lability of Phosphorylated Biomarkers of the DNA Damage Response Pathway Results in Increased Vulnerability to Effects of Delayed or Incomplete Formalin Fixation.
Elizabeth J Wiseman, Jennifer I Moss, James Atkinson, Hana Baakza, Emily Hayes, Gemma N Jones

J Histochem Cytochem· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy professionals in critical care: A UK wide workforce survey.
Paul Twose, Ella Terblanche, Una Jones, James Bruce, Penelope Firshman, Gemma Jones

J Intensive Care Soc· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
Violeta Serra, Anderson T Wang, Marta Castroviejo-Bermejo, Urszula M Polanska, Marta Palafox, Gemma N Jones

Clin Cancer Res· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
Zena Wilson, Rajesh Odedra, Yann Wallez, Paul W G Wijnhoven, Adina M Hughes, Gemma N Jones

Cancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
Sophie E Willis, Claudia Winkler, Martine P Roudier, Tarrion Baird, Paola Marco-Casanova, Emma V Jones, Gemma N Jones

Br J Cancer· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integration and functional performance of a decellularised porcine superflexor tendon graft in an ovine model of anterior cruciate ligament reconstruction.
Jennifer Helen Edwards, Gemma Louise Jones, Anthony Herbert, John Fisher, Eileen Ingham

Biomaterials· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploration of therapists' views of practice within critical care.
Paul Twose, Una Jones, Mina Bharal, James Bruce, Penelope Firshman, Gemma Jones

BMJ Open Respir Res· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study.
Timothy A Yap, Matthew G Krebs, Sophie Postel-Vinay, Anthony El-Khouiery, Jean-Charles Soria, Gemma N Jones

Clin Cancer Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
Johanne I Weberpals, Trevor J Pugh, Paola Marco-Casanova, Glenwood D Goss, Natalie Andrews Wright, Gemma N Jones

Cancer Med· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.
Claudia Winkler, Joshua Armenia, Gemma N Jones, Luis Tobalina, Matthew J Sale

Br J Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Li-An K Brown, Nick Freemantle, Judy Breuer, Hakim-Moulay Dehbi, Kashfia Chowdhury, Gemma Jones

Trials· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of UV-C Decontamination of Clinical Tissue Sections for Spatially Resolved Analysis by Mass Spectrometry Imaging (MSI).
Andreas Dannhorn, Stephanie Ling, Steven Powell, Eileen McCall, Gareth Maglennon, Gemma N Jones

Anal Chem· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Stephanie Lheureux, Mihaela C Cristea, Jeffrey P Bruce, Swati Garg, Michael Cabanero, Gemma N Jones

Lancet· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
Rebecca L Lloyd, Paul W G Wijnhoven, Antonio Ramos-Montoya, Zena Wilson, Giuditta Illuzzi, Gemma N Jones

Oncogene· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically.
Lucy C Riches, Antonio G Trinidad, Gareth Hughes, Gemma N Jones, Adina M Hughes

Mol Cancer Ther· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing care of patients requiring a tracheostomy: A sustained quality improvement project.
Paul Twose, Gemma Jones, Jennifer Lowes, Paul Morgan

J Crit Care· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time-dependent forgetting and retrieval practice effects in detailed visual long-term memory.
Tom Mercer, Gemma A Jones

Q J Exp Psychol (Hove)· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.
Gemma N Jones, Claire Rooney, Nicola Griffin, Martine Roudier, Lucy A Young

Br J Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis